Skip to content
Open access · US-GOV via ClinicalTrials.gov Clinical trial

Effect of Intravitreal Anti-Vascular Endothelial Growth Factors on Retinal Vessels Diameter

Authors not listed

University of Malaya · 2012

Abstract

Patients who will be scheduled for intravitreal injection of Ranibizumab or Bevacizumab will be recruited in this prospective self-controlled trial. Fundus photography will carried out at baseline immediately before injection and at 3, 7 days and 30 days after the first injection. Using image analysis software, measurements summarized as the central retinal artery equivalent (CRAE) and central retinal vein equivalent (CRVE). Null Hypothesis: There is no significant difference between arteriolar/venular diameter before and after injection of intravitreal ranibizumab/bevacizumab in the treated and untreated eye

◌ CITATION ONLY
Full text is not openly licensed for redistribution here. Read it at the source:

Read at source →

Provenance

Source
ClinicalTrials.gov
Canonical
link ↗
Fetched
2026-11-02 MST

Cite this

APA
Anonymous. (2012). Effect of Intravitreal Anti-Vascular Endothelial Growth Factors on Retinal Vessels Diameter. <em>University of Malaya</em>. https://clinicaltrials.gov/study/NCT01626339
Vancouver
Anonymous. Effect of Intravitreal Anti-Vascular Endothelial Growth Factors on Retinal Vessels Diameter. University of Malaya. 2012.
BibTeX
@misc{anon2012Effect, title = {Effect of Intravitreal Anti-Vascular Endothelial Growth Factors on Retinal Vessels Diameter}, author = {Anonymous}, journal = {University of Malaya}, year = {2012}, }

Research neighborhood

References, citing works, and semantically nearest findings. Click a node to open it.

Related findings